431 related articles for article (PubMed ID: 17284570)
1. Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation.
Granado M; Martín AI; Villanúa MA; López-Calderón A
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1656-65. PubMed ID: 17284570
[TBL] [Abstract][Full Text] [Related]
2. Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle.
Granado M; Priego T; Martín AI; Villanúa MA; López-Calderón A
Am J Physiol Endocrinol Metab; 2005 Dec; 289(6):E1007-14. PubMed ID: 16030067
[TBL] [Abstract][Full Text] [Related]
3. Tumour necrosis factor blockade did not prevent the increase of muscular muscle RING finger-1 and muscle atrophy F-box in arthritic rats.
Granado M; Martín AI; Priego T; López-Calderón A; Villanúa MA
J Endocrinol; 2006 Oct; 191(1):319-26. PubMed ID: 17065414
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 inhibition reverts the decrease in adiponectin levels and attenuates the loss of white adipose tissue during chronic inflammation.
Granado M; Martín AI; Castillero E; López-Calderón A; Villanúa MA
Eur J Pharmacol; 2009 Apr; 608(1-3):97-103. PubMed ID: 19239908
[TBL] [Abstract][Full Text] [Related]
5. Short-term growth hormone or IGF-I administration improves the IGF-IGFBP system in arthritic rats.
López-Menduiña M; Martín AI; Castillero E; Villanúa MA; López-Calderón A
Growth Horm IGF Res; 2012 Feb; 22(1):22-9. PubMed ID: 22244673
[TBL] [Abstract][Full Text] [Related]
6. Systemic IGF-I administration attenuates the inhibitory effect of chronic arthritis on gastrocnemius mass and decreases atrogin-1 and IGFBP-3.
López-Menduiña M; Martín AI; Castillero E; Villanúa MA; López-Calderón A
Am J Physiol Regul Integr Comp Physiol; 2010 Aug; 299(2):R541-51. PubMed ID: 20519361
[TBL] [Abstract][Full Text] [Related]
7. Effect of cyclooxygenase-2 inhibition by meloxicam, on atrogin-1 and myogenic regulatory factors in skeletal muscle of rats injected with endotoxin.
Martin AI; Nieto-Bona MP; Castillero E; Fernandez-Galaz C; Lopez-Menduina M; Gomez-Sanmiguel AB; Gomez-Moreira C; Villanua MA; Lopez-Calderon A
J Physiol Pharmacol; 2012 Dec; 63(6):649-59. PubMed ID: 23388481
[TBL] [Abstract][Full Text] [Related]
8. Melanocortin-4 receptor agonist (RO27-3225) ameliorates soleus but not gastrocnemius atrophy in arthritic rats.
Gomez-Sanmiguel AB; Nieto-Bona MP; Fernandez-Galaz C; Priego T; Martin AI; Lopez-Calderon A
J Physiol Pharmacol; 2017 Apr; 68(2):191-199. PubMed ID: 28614768
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor necrosis factor agent PEG-sTNFRI improves the growth hormone/insulin-like growth factor-I system in adjuvant-induced arthritic rats.
Granado M; Priego T; Martín AI; Vara E; López-Calderón A; Angeles Villanúa M
Eur J Pharmacol; 2006 Apr; 536(1-2):204-10. PubMed ID: 16545800
[TBL] [Abstract][Full Text] [Related]
10. Ghrelin inhibits skeletal muscle protein breakdown in rats with thermal injury through normalizing elevated expression of E3 ubiquitin ligases MuRF1 and MAFbx.
Balasubramaniam A; Joshi R; Su C; Friend LA; Sheriff S; Kagan RJ; James JH
Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R893-901. PubMed ID: 19211729
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate, a PPAR{alpha} agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy.
Castillero E; Nieto-Bona MP; Fernández-Galaz C; Martín AI; López-Menduiña M; Granado M; Villanúa MA; López-Calderón A
Am J Physiol Endocrinol Metab; 2011 May; 300(5):E790-9. PubMed ID: 21304067
[TBL] [Abstract][Full Text] [Related]
12. IGF-I system, atrogenes and myogenic regulatory factors in arthritis induced muscle wasting.
Castillero E; Martín AI; López-Menduiña M; Granado M; Villanúa MA; López-Calderón A
Mol Cell Endocrinol; 2009 Oct; 309(1-2):8-16. PubMed ID: 19501629
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of inducible nitric oxide synthase reverts arthritic-induced decrease in pituitary growth hormone mRNA but not in liver insulin-like growth factor I mRNA expression.
Ibáñez de Cáceres I; Priego T; Martín AI; López-Calderón A; Villanúa MA
J Neuroendocrinol; 2003 Dec; 15(12):1178-84. PubMed ID: 14636180
[TBL] [Abstract][Full Text] [Related]
14. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
15. AMP-activated protein kinase agonists increase mRNA content of the muscle-specific ubiquitin ligases MAFbx and MuRF1 in C2C12 cells.
Krawiec BJ; Nystrom GJ; Frost RA; Jefferson LS; Lang CH
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1555-67. PubMed ID: 17264220
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 [corrected] activation by endotoxin mediates the decrease in IGF1, but not in IGFBP3, [corrected] gene expression in the liver.
Martín AI; López-Menduiña M; Castillero E; Granado M; Villanúa MA; López-Calderón A
J Endocrinol; 2008 Aug; 198(2):385-94. PubMed ID: 18492809
[TBL] [Abstract][Full Text] [Related]
17. Eicosapentaenoic acid attenuates arthritis-induced muscle wasting acting on atrogin-1 and on myogenic regulatory factors.
Castillero E; Martín AI; López-Menduiña M; Villanúa MA; López-Calderón A
Am J Physiol Regul Integr Comp Physiol; 2009 Nov; 297(5):R1322-31. PubMed ID: 19741054
[TBL] [Abstract][Full Text] [Related]
18. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1.
Sacheck JM; Ohtsuka A; McLary SC; Goldberg AL
Am J Physiol Endocrinol Metab; 2004 Oct; 287(4):E591-601. PubMed ID: 15100091
[TBL] [Abstract][Full Text] [Related]
19. AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes.
Tong JF; Yan X; Zhu MJ; Du M
J Cell Biochem; 2009 Oct; 108(2):458-68. PubMed ID: 19639604
[TBL] [Abstract][Full Text] [Related]
20. Role of the insulin-like growth factor I decline in the induction of atrogin-1/MAFbx during fasting and diabetes.
Dehoux M; Van Beneden R; Pasko N; Lause P; Verniers J; Underwood L; Ketelslegers JM; Thissen JP
Endocrinology; 2004 Nov; 145(11):4806-12. PubMed ID: 15284206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
